
Bingham and colleagues provide new and timely information about the relationships among cancer chemotherapies and immune-related unwanted events—a potential new era of emerging rheumatic diseases brought on by advances in other fields. Sivaraman and Cohen address the management of RA and the risk of malignancies when utilizing Janus Kinase inhibition; this is clearly an emerging topic as the development of these drugs comes center stage. Calabrese and colleagues discuss progressive multifocal leukoencephalopathy or PML in the setting of our diseases and immune-suppressing drugs—the rare event causing a devastating outcome. Strategies to improve outcome are noted. Eliza Chakravarty provides a stunningly comprehensive review of herpes zoster incidence, pathogenesis, and prevention. The impact of hepatitis C and the rheumatologist is carefully analyzed by Cacoub and colleagues. The risk for hepatitis B reactivation during immunosuppression is continuing to be an ongoing problem for those of us that use biologic agents and care for rheumatic disease patients; Koutsianas and colleagues carefully talk about detection, prophylaxis, and treatment.
I am notably and especially proud of this effort to bring so many important issues together in one issue in the Rheumatic Disease Clinics of North America . Congrats to the editors and contributors.

Stay updated, free articles. Join our Telegram channel

Full access? Get Clinical Tree

